Prostate Cancer Staging: Understanding TNM, Gleason, and Grade Groups

A prostate cancer diagnosis includes multiple staging systems that together determine prognosis and guide treatment decisions. Understanding these systems — TNM staging, Gleason score, and the newer Grade Group classification — enables men to participate meaningfully in their own care.

This article explains what each system measures, how they interact, and what the risk stratification categories mean for treatment planning.

The TNM Staging System

TNM staging describes the anatomical extent of the tumor. It is the universal cancer staging framework applied across all solid tumors.

T — Primary Tumor

Most men diagnosed today are T1c — diagnosed by biopsy triggered by elevated PSA, with no palpable tumor on rectal exam.

N — Regional Lymph Nodes

• N0: No regional lymph node involvement
• N1: Metastasis to regional (pelvic) lymph nodes

M — Distant Metastasis

• M0: No distant metastasis
• M1a: Non-regional lymph node metastasis
• M1b: Bone metastasis (most common site)
• M1c: Other organ metastasis (liver, lung, etc.)

Most men diagnosed with prostate cancer today are M0 — disease confined to the prostate or regional structures without distant spread.

The Gleason Grading System

The Gleason score describes tumor aggressiveness based on the microscopic pattern of cancer cells under the pathologist's microscope. It was developed by Donald Gleason in the 1960s and modified in 2005 and 2014.

How Gleason Score Works

The pathologist evaluates the two most prevalent architectural patterns in the biopsy tissue and assigns each a grade from 1–5 (though Grades 1 and 2 are no longer assigned in modern practice):

• Grade 3: Small, well-formed glands resembling normal prostate tissue
• Grade 4: Poorly formed, fused, or absent glands
• Grade 5: No glandular differentiation; solid sheets or individual cells

The Gleason score = primary pattern + secondary pattern. For example, Gleason 3+4=7 means the predominant pattern is grade 3, with grade 4 as the secondary pattern.

Higher grades = more aggressive, faster-growing cancer.

Modern Gleason Reporting

Current reporting always includes:

• The score (e.g., 3+4=7)
• The percentage of high-grade (grade 4 or 5) tissue in positive cores
• The number of positive biopsy cores out of total cores taken

Grade Groups: The Current Standard

The International Society of Urological Pathology (ISUP) Grade Group system was introduced in 2014 to address limitations of Gleason scoring and has become the preferred reporting standard. [^epstein2016]

Grade Group 2 and 3 are both Gleason 7 but have meaningfully different prognoses. Grade Group 2 (3+4) has predominantly well-formed glands with a minority of high-grade tissue; Grade Group 3 (4+3) has predominantly high-grade tissue. This distinction matters: [^pierorazio2013]

• Grade Group 2: 10-year biochemical recurrence-free survival ~85%
• Grade Group 3: 10-year biochemical recurrence-free survival ~70%

The Grade Group system also solved a psychological problem: patients received a diagnosis of "Gleason 6" cancer, which sounds severe. Grade Group 1 better communicates the actual low-risk nature of the disease.

Risk Stratification

Staging combines T, N, M, PSA level, and Grade Group into risk categories that guide treatment recommendations. The NCCN (National Comprehensive Cancer Network) system is the most widely used. [^nccn2023]

PSA in Staging

PSA (prostate-specific antigen) at diagnosis is a key staging element. Higher PSA at diagnosis predicts higher disease burden and greater risk of extracapsular extension or spread:

• PSA <10 ng/mL: lower risk category (with other favorable features)
• PSA 10–20 ng/mL: intermediate risk contributor
• PSA >20 ng/mL: high-risk feature

PSA velocity (rate of rise before diagnosis) and PSA density (PSA/prostate volume) provide additional prognostic information — particularly in distinguishing aggressive from indolent disease in the low-PSA range. [^briganti2012]

Imaging in Staging

Multiparametric MRI (mpMRI): Used for local staging — assessing extracapsular extension, seminal vesicle involvement, and identifying suspicious areas for targeted biopsy. Increasingly standard in the diagnostic workup. MRI-visible lesions are described using the PI-RADS scoring system (1–5).

Bone scan: Recommended for PSA >20, Grade Group 4–5, or T3–T4 disease to detect bone metastases (M1b).

PSMA PET scan: Increasingly replacing bone scan and CT for staging due to superior sensitivity for detecting metastatic disease, particularly at low PSA levels. Best available imaging for detecting pelvic lymph node involvement and distant spread.

CT abdomen/pelvis: Used to assess lymph node involvement (N staging) in intermediate/high-risk patients.

What Staging Determines

Staging directly guides treatment selection:

Very low / Low risk: Active surveillance is the recommended initial approach for most men. Curative treatment (surgery or radiation) is an option but may be deferred indefinitely if disease remains stable. [^tosoian2011]

Favorable intermediate risk: Active surveillance is appropriate for selected patients; others proceed to surgery or radiation.

Unfavorable intermediate risk: Curative treatment with radiation plus short-course androgen deprivation therapy, or radical prostatectomy.

High/Very high risk: Radiation plus longer-course androgen deprivation therapy; or radical prostatectomy in select patients. Multimodal treatment is standard.

Regional (N1): Radiation plus prolonged androgen deprivation therapy; or surgery with planned adjuvant therapy.

Metastatic (M1): Systemic treatment — androgen deprivation therapy ± chemotherapy ± novel hormonal agents depending on volume and castration sensitivity.

Biochemical Recurrence

After curative treatment (surgery or radiation), PSA should become undetectable or very low. Biochemical recurrence — PSA rise after treatment — is defined differently depending on treatment type:

• After radical prostatectomy: PSA ≥0.2 ng/mL on two consecutive measurements
• After radiation: PSA rise of 2 ng/mL above nadir (lowest point) — the Phoenix definition [^roach2006]

Biochemical recurrence does not necessarily mean clinical recurrence or reduced survival — many men with rising PSA after treatment have very long natural histories before clinical progression.

Bottom Line

Prostate cancer staging integrates tumor extent (TNM), pathological aggressiveness (Gleason/Grade Group), and PSA level into risk categories that drive treatment decisions. Grade Group 1 (Gleason 6) disease carries a very favorable prognosis and is appropriate for active surveillance in most men. The distinction between Grade Group 2 and 3 within the Gleason 7 category is clinically meaningful. High and very high-risk disease requires more aggressive multimodal treatment. Understanding your specific staging components enables informed shared decision-making with your urologist or oncologist.